What is HC Wainwright’s Forecast for DVAX FY2024 Earnings?

Dynavax Technologies Co. (NASDAQ:DVAX) – Equities researchers at HC Wainwright upped their FY2024 earnings estimates for shares of Dynavax Technologies in a report issued on Friday, November 8th. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will post earnings per share of $0.18 for the year, up from their previous estimate of $0.17. HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.18 per share. HC Wainwright also issued estimates for Dynavax Technologies’ Q4 2024 earnings at $0.04 EPS and FY2025 earnings at $0.26 EPS.

Separately, The Goldman Sachs Group reduced their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $13.66 on Monday. The company has a fifty day simple moving average of $11.16 and a 200 day simple moving average of $11.24. Dynavax Technologies has a 12-month low of $9.74 and a 12-month high of $15.01. The company has a current ratio of 14.18, a quick ratio of 13.18 and a debt-to-equity ratio of 0.35. The company has a market cap of $1.79 billion, a P/E ratio of 105.01 and a beta of 1.34.

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Dynavax Technologies by 1.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 1,172 shares during the last quarter. SummerHaven Investment Management LLC boosted its holdings in Dynavax Technologies by 2.4% during the 2nd quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 1,303 shares during the last quarter. Texas Permanent School Fund Corp boosted its holdings in Dynavax Technologies by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company’s stock worth $1,404,000 after acquiring an additional 1,467 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.